Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Skin-related Diseases/Disorders and Ageing Population
4.2.2 Increasing Demand and Availability of Dermatological OTC Drugs
4.3 Market Restraints
4.3.1 Side Effects Associated With the OTC Medications
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Indication
5.1.1 Acne
5.1.2 Dermatitis
5.1.3 Psoriasis
5.1.4 Fungal Infections
5.1.5 Others
5.2 By Product
5.2.1 Tablets and Capsules
5.2.2 Oils, Gels, Creams, and Ointments
5.2.3 Others
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Topical
5.4 By Distribution Channel
5.4.1 Hospital and Retail Pharmacies
5.4.2 Online Pharmacies
5.4.3 Others
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Spain
5.5.2.5 Italy
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Perrigo Company plc
6.1.2 Bausch Health Companies Inc.
6.1.3 Dr. Reddy’s Laboratories
6.1.4 Johnson and Johnson
6.1.5 Bayer AG
6.1.6 GlaxoSmithKline plc.
6.1.7 Viatris Inc
6.1.8 LEO Pharma A/S
6.1.9 Acella Pharmaceuticals, LLC
6.1.10 Teva Pharmaceutical Industries Ltd.
6.1.11 Galderma


7 MARKET OPPORTUNITIES AND FUTURE TRENDS